Literature DB >> 6702873

Neutropenia, fever, and infection.

A E Brown.   

Abstract

With the advances in the management of various neoplastic diseases and subsequent improvement in "disease-free" states, complications of therapy--particularly, infectious complications--have evolved as stumbling blocks to survival. Among neutropenic (absolute neutrophil count below 1,000/mm3) patients with cancer, infection is the major autopsy-determined cause of death. With expected "cure rates" of childhood leukemia approaching 60 to 70 percent, it seems unreasonable to lose such patients to an infectious cause of death, yet this, indeed, happens. The purpose of this review is to (1) define the magnitude of the problem; (2) describe the various agents responsible for infections in neutropenic patients; (3) attempt to more sharply define degrees of neutropenia and mechanical defenses; and (4) consider various approaches to studying and treating these infections.

Entities:  

Mesh:

Year:  1984        PMID: 6702873     DOI: 10.1016/0002-9343(84)90661-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  32 in total

Review 1.  [Therapy of infections in patients with acute leukemia].

Authors:  W Hiddemann; G Maschmeyer; H Link; M Helmerking; D Adam
Journal:  Med Klin (Munich)       Date:  1997-07-15

2.  Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.

Authors:  M Tod; O Lortholary; D Seytre; R Semaoun; B Uzzan; L Guillevin; P Casassus; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis.

Authors:  W Kern; K Linzmeier; E Kurrle
Journal:  Infection       Date:  1989 Nov-Dec       Impact factor: 3.553

4.  Population pharmacokinetic study of teicoplanin in severely neutropenic patients.

Authors:  O Lortholary; M Tod; N Rizzo; C Padoin; O Biard; P Casassus; L Guillevin; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia.

Authors:  D Faulds; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

Review 6.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients.

Authors:  B S Kramer; R Ramphal; K H Rand
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

8.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases.

Authors:  W Kern; E Kurrle; T Schmeiser
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

10.  Ceftazidime with or without amikacin for the empiric treatment of localized infections in febrile, granulocytopenic patients.

Authors:  I R Nováková; J P Donnelly; B E de Pauw
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.